Artal Group’s Cymabay Therapeutics CBAY Stock Holding History

Artal Group’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-303,600	Closed	-$7.17M	–	129
2023 Q4	$7.17M	Buy	+303,600	New	+$5.41M	0.24%	41
2019 Q2	–	Sell	-600,000	Closed	-$7.97M	–	122
2019 Q1	$7.97M	Buy	600,000 +100,000	+20%	+$1.06M	0.33%	62
2018 Q4	$3.94M	Sell	500,000 -300,000	-38%	-$2.86M	0.15%	74
2018 Q3	$8.86M	Hold	800,000	–	–	0.23%	58
2018 Q2	$10.7M	Buy	800,000 +400,000	+100%	+$5.01M	0.23%	47
2018 Q1	$5.2M	Buy	+400,000	New	+$4.97M	0.07%	67

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Artal Group's CBAY Position: Q1 2024 in Review

Artal Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 303,600 shares — an estimated $7.17M sold.

Artal Group first reported a position in CBAY in Q1 2018 and held it in 6 quarters. The position peaked at $10.7M in Q2 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Artal Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Artal Group sold 303,600 Cymabay Therapeutics shares in Q1 2024, an estimated $7.17M.
Artal Group first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 6 quarters.
Artal Group's Cymabay Therapeutics position peaked at $10.7M in Q2 2018.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.